Welcome to the 2026 Annual Stockholders Meeting of Beam Therapeutics. I will now turn the call over to John Evans. Please go ahead.
Thank you, and thanks for joining us today. My name is John Evans, and I am the Chief Executive Officer and a director of Beam Therapeutics. Beam Therapeutics is a biotechnology company developing precision genetic medicines through an innovative form of gene editing called base editing. I'm pleased to welcome you to our 2026 Annual Meeting of Stockholders. We're excited to be hosting our virtual meeting live via webcast, which allows us to be more inclusive and reach a greater number of our stockholders. As a company focused on the development and commercialization of innovative therapies, we view this meeting format as a way to be more efficient in our meeting process, which ultimately benefits all of our shareholders. Hosting a virtual annual meeting also facilitates shareholder attendance and participation fully and equally from any location in the world.
Shareholders attending via the web portal can access a copy of the agenda and the rules of procedure for today's meeting. You may ask questions regarding the proposals being voted on at this meeting and in accordance with these rules. Please submit pertinent questions via the web portal. Questions will be answered prior to the closing of the polls. Although we may not be able to answer every question, we will do our best to provide a response to as many as possible. Before I call the meeting to order, I'd like to introduce you to the other members of our board, which are Graham Cooper, Mark Fishman, Chirfi Guindo, John Maraganore, Christi Shaw, and Kate Walsh.
I would also like to introduce Brian McAllister of Deloitte & Touche, or Deloitte, the company's independent auditor, who will be available to respond to any questions you may have regarding the appointment of Deloitte as the company's independent registered public accountants. At this time, I call the meeting to order and will now turn the meeting over to Chris Bellon, who will serve as secretary for today's meeting.
Thanks, John. Just a reminder that validated stockholders may ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to one question. The meeting is being recorded, no one attending via the webcast is permitted to use any recording device. All stockholders of record at the close of business on April 7th, 2026, or holders of a valid proxy who entered the meeting using their 16-digit control number, will be able to ask a question and are entitled to vote at today's meeting. Notice of the meeting was first sent or made available on April 17th, 2026, to all stockholders of record as of the close of business on the record date. The company has appointed attorney Jenna Bentley to act as the Inspector of Election.
The Inspector of Election has informed us that a quorum is present, so we can now proceed with the formal business of the meeting. The polls are now open for voting on all matters before the meeting. We will now proceed to the discussion of the proposals. There are three items of business to be considered by the stockholders at today's meeting. Please note that we will give stockholders an opportunity to ask questions related to the proposals after all proposals have been presented. The first item of business is a proposal to elect John Evans, John Maraganore, and Christi Shaw to serve as Class III directors for terms ending in 2029. Our board recommends that stockholders vote for the director nominees. The second item of business is a proposal to ratify the Audit Committee's appointment of Deloitte as the company's independent auditor for 2026.
Our board recommends that stockholders vote for this proposal. The third and final item of business is a proposal to approve, on an advisory basis, the compensation of our named executive officers as disclosed in our proxy statement. Our board recommends that stockholders vote for this proposal. We will pause for 30 seconds in case any stockholder would like to ask a question regarding any of these proposals. Questions can be submitted through the web portal.
Thank you. There are no questions at this time.
Please note that you do not need to vote during the meeting if you have already sent in your signed proxy, or if you have voted by telephone or internet. Any stockholder who has not yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. We will pause for 30 seconds in case anyone would like to vote. Now that everyone has had the opportunity to vote, the polls are now closed for voting on the proposals before the meeting. According to the Inspector of Election, the preliminary voting report shows that the nominees for election to the board have been duly elected, the appointment of Deloitte as the company's independent auditor for 2026 has been ratified, and the compensation of our named executive officers has been approved.
We will disclose the final tally of the votes in a current report on Form 8-K that we will file within four business days after this meeting. There being no other business, this meeting is now adjourned. I want to thank you for attending and for your support of Beam Therapeutics.
This concludes today's meeting. You may now disconnect.